Florida-based probiotic company, Oragenics, Inc. (OTCQB: ORNI), announced today that Chief Executive Officer, John N. Bonfiglio, Ph.D., was one of the featured speakers on January 10th, 2012 at Biotech Showcase? 2012, a prestigious business forum for innovative life science companies to interact with the investment and business community.

The Biotech Showcase? presentation focused on the unique positioning of Oragenics in the oral care probiotics market, particularly through its marketing focus on private label and branded products both domestically and overseas. In his remarks, Dr. Bonfiglio discussed some of the major contract activities in the US and in Europe. Dr. Bonfiglio described the various product marketing channels being successfully utilized by the company including, "direct to consumer", "private label relationships" and "direct marketing to dental professionals."

Oragenics recently released a corporate video, which further elaborates management's strategic vision. The video can be accessed on Oragenics' corporate site www.oragenics.com as well as Facebook, YouTube, and other informative news feeds.

"Given the important role oral care plays in supporting overall health, the intent of the video and the Biotech Showcase? appearance is to broaden the awareness of probiotics for oral care and to share Oragenics' vision going forward in 2012," stated Dr. Bonfiglio. "Our unique platform technology, ProBiora3® and its important role in providing a suite of outstanding Evora® brand oral care probiotic products, is profiled in the video. We are proud that our proprietary products are currently sold in over 20 countries, with many opportunities for geographic and industry sector expansion being developed through our current marketing initiatives. We are also excited about expanding our products' claims and utility through the addition of new delivery vehicles and additional health claims," added Dr. Bonfiglio.

About Oragenics, Inc.

Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The Company's proprietary products Evora® and ProBiora3® are currently sold in over 20 countries. In addition, Oragenics has a robust pipeline of therapeutic products targeting infectious disease.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

For more information visit www.oragenics.com.

Oragenics, Inc.
Corporate Contact:
Linda Loren, 813-527-1020
Marketing Director
lloren@oragenics.com
or
Cooper Global Communications
Investor Contact:
Jennifer K. Zimmons, Ph.D., 212-209-7360
Managing Director
jzimmons@cgc-us.com